New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma;Nowy analog somatostatyny 99mTc-HYNIC-TOC w diagnostyce scyntygraficznej raka rdzeniastego tarczycy

Polskie Archiwum Medycyny Wewnetrznej

Volumn 116, Issue 3, 2006, Pages 853-860

  Czepczyński, Rafał ^a   Kosowicz, Jerzy ^a   Mikołajczak, Renata ^b   Ziemnicka, Katarzyna ^a   Gryczyńska, Maria ^a   Sowiński, Jerzy ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

Author keywords

Medullary thyroid carcinoma; Peptide receptor scintigraphy; Somatostatin analogues

Indexed keywords

CALCITONIN; HYDRAZINONICOTINYLTYROSINE 3 OCTREOTIDE TC 99M; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; TECHNETIUM 99M; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; OCTREOTIDE; TECHNETIUM COMPLEX; TECHNETIUM TC 99M TRICINE HYDRAZINONICOTINYL PHE(1) TYR(3) OCTREOTIDE; TECHNETIUM TC 99M-TRICINE-HYDRAZINONICOTINYL-PHE(1)-TYR(3)-OCTREOTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; MALE; PREOPERATIVE EVALUATION; SCINTISCANNING; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING; BLOOD; COMPARATIVE STUDY; LABORATORY DIAGNOSIS; MEDULLARY CARCINOMA; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALCITONIN; CARCINOMA, MEDULLARY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 33846799017     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Shoback D., Marcus R., Bikle D., Strewler G.: Medullary thyroid carcinoma, [w:] Greenspan F.S., Gardner D.G. (red.) Basic & Clinical Endocrinology. Lange Medical Books/McGraw-Hill; 6th edition. New York 2001.
2. Quayle F.J., Moley J.F.: Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J. Surg. Oncol., 2005, 89, 122.
3. Moley J.F.: Medullary thyroid carcinoma. Curr. Treat. Options. Oncol., 2003, 4), 339.
4. Hanna F.W.F., Ardill J.E.S., Johnston C.F. i wsp.: Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid. J. Endocrinol., 1997, 152, 275.
5. DeLellis R.A., Rule A.M., Spiler I., Nathanson L., Tashjian A.H., Wolfe H.J.: Calcitonin and carcinoembyogenic antigen as tumour markers in medullary thyroid carcinoma. Am. J. Clin. Pathol., 1978, 70, 587.
6. Saller B., Moeller L., Gorges R., Janssen O.E., Mann K.: Role of conventional ultrasound and color Doppler sonography in the diagnosis of medullary thyroid carcinoma. Exp. Clin. Endocrinol. Diabetes., 2002, 110, 403.
7. Wang Q., Takashima S., Fukuda H., Takayama F., Kobayashi S., Sone S.: Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch. Otolaryngol. Head. Neck. Surg., 2002, 125, 842.
8. Arslan N., Ilgan S., Yuksel D. i wsp.: Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin. Nucl. Med., 2001, 26, 683.
9. 99mTc-labelled radio-pharmacuetical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur. J. Nucl. Med., 2000, 27, 1318.
10. 111In-DTPA-Octreotide for diagnosis of somatostatin receptor expressing tumors. J. Nucl. Med., 2003, 44, 708.
11. Warner R.R., O'dorisio T.M.: Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin. Nucl. Med., 2002, 32, 79.
12. Diehl M., Risse J.H., Brandt-Mainz K. i wsp.: Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur. J. Nucl. Med., 2001, 28, 1671.
13. 111In-DTPA-D-Phe1-octreotide. Eur. J. Nucl. Med., 2000, 27, 628.
14. 111In-DTPA0] octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J. Nucl. Med., 2005, 46, 1561.
15. Płachcińska A., Mikołajczak R., Maecke H.R. i wsp.: Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1402.
16. 99mTc-EDDA/HYNIC-TATE - nowy analog w diagnostyce lokalizacyjnej rakowiaków - 2-letnie doświadczenia. Endokrynol. Pol., 2005, 56, 485.
17. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma. Cancer. Biother. Radiopharm., 2004, 19, 211.
18. de Groot J.W., Links T.P., Jager P.L., Kahraman T., Plukker J.T.: Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann. Surg. Oncol., 2004, 11, 786.
19. Kwekkeboom D.J., Muller-Brand J., Paganelli G. i wsp.: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med., 2005, 46, 62S.
20. Bodei L., Handkiewicz-Junak D., Grana C. i wsp.: Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother. Radiopharm., 2004, 19, 65.